Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models

Neurobiology of Disease

Volumn 40, Issue 3, 2010, Pages 565-572

  Willis, Sarah ^a   Stoll, James ^a   Sweetman, Lawrence ^b   Borges, Karin ^a,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Hydroxybutyrate; Anaplerosis; Corneal kindling; Epilepsy; Pentylenetetrazole; Pilocarpine; Propionyl CoA; Seizure

Indexed keywords

4 AMINOBUTYRIC ACID; ACYLCARNITINE; ASPARTIC ACID; CARNITINE; CITRIC ACID; FUMARIC ACID; GLUTAMIC ACID; GLUTAMINE; HEPTANOIC ACID DERIVATIVE; MALIC ACID; PENTETRAZOLE; PILOCARPINE; PROPIONYL COENZYME A; SUCCINIC ACID; TRIHEPTANOIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BODY WEIGHT; BRAIN METABOLISM; CALORIC INTAKE; CHRONIC DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE PREDISPOSITION; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FOOD COMPOSITION; KINDLING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SEIZURE THRESHOLD; TONIC SEIZURE;

ANIMALS; ANTICONVULSANTS; BRAIN; DISEASE MODELS, ANIMAL; EPILEPSY; MICE; SEIZURES; TRIGLYCERIDES;

EID: 77957790307     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.07.017     Document Type: Article

References (41)

1. Blanco M.M., dos Santos J.G., Perez-Mendes P., Kohek S.R., Cavarsan C.F., Hummel M., Albuquerque C., Mello L.E. Assessment of seizure susceptibility in pilocarpine epileptic and nonepileptic Wistar rats and of seizure reinduction with pentylenetetrazole and electroshock models. Epilepsia 2009, 50:824-831.
2. Borges K., Gearing M., McDermott D.L., Smith A.B., Almonte A.G., Wainer B.H., Dingledine R. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp. Neurol. 2003, 182:21-34.
3. Borges K., Gearing M., Rittling S.R., Sorensen E.S., Kotloski R., Denhardt D.T., Dingledine R. Characterization of osteopontin expression and function after status epilepticus. Epilepsia 2008, 49:1675-1685.
4. Borges K., McDermott D., Irier H., Smith Y., Dingledine R. Degeneration and proliferation of astrocytes in the mouse dentate gyrus after pilocarpine-induced status epilepticus. Exp. Neurol. 2006, 201:416-427.
5. Borges K., McDermott D.L., Dingledine R. Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice. Exp. Neurol. 2004, 188:1-10.
6. Bough K.J., Wetherington J., Hassel B., Pare J.F., Gawryluk J.W., Greene J.G., Shaw R., Smith Y., Geiger J.D., Dingledine R.J. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol. 2006, 60:223-235.
7. Brandt C., Heile A., Potschka H., Stoehr T., Loscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006, 47:1803-1809.
8. Brunengraber H., Roe C.R. Anaplerotic molecules: current and future. J. Inherit. Metab. Dis. 2006, 29:327-331.
9. Curia G., Longo D., Biagini G., Jones R.S., Avoli M. The pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods 2008, 172:143-157.
10. de Almeida Rabello Oliveira M., da Rocha Ataide T., de Oliveira S.L., de Melo Lucena A.L., de Lira C.E., Soares A.A., de Almeida C.B., Ximenes-da-Silva A. Effects of short-term and long-term treatment with medium- and long-chain triglycerides ketogenic diet on cortical spreading depression in young rats. Neurosci. Lett. 2008, 434:66-70.
11. Garriga-Canut M., Schoenike B., Qazi R., Bergendahl K., Daley T.J., Pfender R.M., Morrison J.F., Ockuly J., Stafstrom C., Sutula T., Roopra A. 2-Deoxy-d-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat. Neurosci. 2006, 9:1382-1387.
12. Goldberg N.D., Passonneau J.V., Lowry O.H. Effects of changes in brain metabolism on the levels of citric acid cycle intermediates. J. Biol. Chem. 1966, 241:3997-4003.
13. Hartman A.L., Gasior M., Vining E.P., Rogawski M.A. The neuropharmacology of the ketogenic diet. Pediatr. Neurol. 2007, 36:281-292.
14. Hassel B. Carboxylation and anaplerosis in neurons and glia. Mol. Neurobiol. 2000, 22:21-40.
15. Kinman R.P., Kasumov T., Jobbins K.A., Thomas K.R., Adams J.E., Brunengraber L.N., Kutz G., Brewer W.U., Roe C.R., Brunengraber H. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E860-E866.
16. Kudin A.P., Zsurka G., Elger C.E., Kunz W.S. Mitochondrial involvement in temporal lobe epilepsy. Exp. Neurol. 2009, 218:326-332.
17. Leclerc J., Des Rosiers C., Montgomery J.A., Brunet J., Ste-Marie L., Reider M.W., Fernandez C.A., Powers L., David F., Brunengraber H. Metabolism of R-beta-hydroxypentanoate and of beta-ketopentanoate in conscious dogs. Am. J. Physiol. 1995, 268:E446-E452.
18. Lian X.Y., Khan F.A., Stringer J.L. Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. J. Neurosci. 2007, 27:12007-12011.
19. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 1991, 8:171-189.
20. Matagne A., Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 1998, 31:59-71.
21. Matagne A., Margineanu D.G., Kenda B., Michel P., Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 2008, 154:1662-1671.
22. Mochel F., DeLonlay P., Touati G., Brunengraber H., Kinman R.P., Rabier D., Roe C.R., Saudubray J.M. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol. Genet. Metab. 2005, 84:305-312.
23. Neal E.G., Chaffe H., Schwartz R.H., Lawson M.S., Edwards N., Fitzsimmons G., Whitney A., Cross J.H. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008, 7:500-506.
24. Nordstrom C.H., Rehncrona S., Siesjo B.K. Effects of phenobarbital in cerebral ischemia. Part II: restitution of cerebral energy state, as well as of glycolytic metabolites, citric acid cycle intermediates and associated amino acids after pronounced incomplete ischemia. Stroke 1978, 9:335-343.
25. Pan J.W., Williamson A., Cavus I., Hetherington H.P., Zaveri H., Petroff O.A., Spencer D.D. Neurometabolism in human epilepsy. Epilepsia 2008, 49(Suppl 3):31-41.
26. Puchowicz M.A., Zechel J.L., Valerio J., Emancipator D.S., Xu K., Pundik S., LaManna J.C., Lust W.D. Neuroprotection in diet-induced ketotic rat brain after focal ischemia. J. Cereb. Blood Flow Metab. 2008, 28:1907-1916.
27. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
28. Rashed M.S., Bucknall M.P., Little D., Awad A., Jacob M., Alamoudi M., Alwattar M., Ozand P.T. Screening blood spots for inborn errors of metabolism by electrospray tandem mass spectrometry with a microplate batch process and a computer algorithm for automated flagging of abnormal profiles. Clin. Chem. 1997, 43:1129-1141.
29. Roe C.R., Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J. Inherit. Metab. Dis. 2006, 29:332-340.
30. Roe C.R., Sweetman L., Roe D.S., David F., Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J. Clin. Invest. 2002, 110:259-269.
31. Samala R., Willis S., Borges K. Anticonvulsant profile of a balanced ketogenic diet in acute mouse seizure models. Epilepsy Res. 2008, 81:119-127.
32. Silver J.M., Shin C., McNamara J.O. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy. Ann. Neurol. 1991, 29:356-363.
33. Smith M., Wilcox K.S., White H.S. Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4:12-17.
34. Stafstrom C.E., Ockuly J.C., Murphree L., Valley M.T., Roopra A., Sutula T.P. Anticonvulsant and antiepileptic actions of 2-deoxy-d-glucose in epilepsy models. Ann. Neurol. 2009, 65:435-447.
35. Sweetman L. Organic acid analysis techniques in diagnostic human biochemical genetics: a laboratory manual. Techniques in Diagnostic Human Biochemical Genetics: a Laboratory Manual 1991, 143-176. Wiley-Liss Inc, New York. F. Hommes (Ed.).
36. Turski W.A., Cavalheiro E.A., Bortolotto Z.A., Mello L.M., Schwarz M., Turski L. Seizures produced by pilocarpine in mice: a behavioral, electroencephalographic and morphological analysis. Brain Res. 1984, 321:237-253.
37. Turski W.A., Cavalheiro E.A., Schwarz M., Czuczwar S.J., Kleinrok Z., Turski L. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav. Brain Res. 1983, 9:315-335.
38. Vezzani A., Civenni G., Rizzi M., Monno A., Messali S., Samanin R. Enhanced neuropeptide Y release in the hippocampus is associated with chronic seizure susceptibility in kainic acid treated rats. Brain Res. 1994, 660:138-143.
39. Wang X., Allen F.J., Sayre C., Wan D., Minkler P.E., Hoppel C.L., Brunengraber H. Anaplerosis from heptanoate - a propionyl-CoA precursor - in mouse brain. FASEB 2007, 21:541.12.
40. White H.S. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003, 44(Suppl 7):2-8.
41. Willis S., Samala R., Rosenberger T.A., Borges K. Eicosapentaenoic and docosahexaenoic acids are not anticonvulsant or neuroprotective in acute mouse seizure models. Epilepsia 2009, 50:138-142.